GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (NAS:IDYA) » Definitions » Owner Earnings per Share (TTM)

IDEAYA Biosciences (IDEAYA Biosciences) Owner Earnings per Share (TTM) : -1.87 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is IDEAYA Biosciences Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

IDEAYA Biosciences's Owner Earnings per Share (TTM) ended in Mar. 2024 was $-1.87. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for IDEAYA Biosciences's Owner Earnings per Share (TTM) or its related term are showing as below:



IDYA's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.67
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

IDEAYA Biosciences's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.53. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.01. It's PE Ratio ratio for today is At Loss.

IDEAYA Biosciences's EPS without NRI for the three months ended in Mar. 2024 was $-0.51. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.99. It's PE Ratio without NRI ratio for today is At Loss.


IDEAYA Biosciences Owner Earnings per Share (TTM) Historical Data

The historical data trend for IDEAYA Biosciences's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEAYA Biosciences Owner Earnings per Share (TTM) Chart

IDEAYA Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial - - - -2.08 -1.89

IDEAYA Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.20 -2.11 -2.06 -1.89 -1.87

Competitive Comparison of IDEAYA Biosciences's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, IDEAYA Biosciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEAYA Biosciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where IDEAYA Biosciences's Price-to-Owner-Earnings falls into.



IDEAYA Biosciences Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

IDEAYA Biosciences's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -130.38
Depreciation, Depletion and Amortization 4.13
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 2.69
Change In Working Capital -11.26
Shares Outstanding (Diluted Average) 75.11

1. Start with "Net Income" from income statement. IDEAYA Biosciences's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-130.38 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. IDEAYA Biosciences's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2024 was $4.13 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. IDEAYA Biosciences's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $2.69 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

IDEAYA Biosciences's 5-Year Average Maintenance Capital Expenditure = $2.69 Mil

5. "Change In Working Capital" is from cashflow statement. IDEAYA Biosciences's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 was $-11.26 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. IDEAYA Biosciences's Shares Outstanding (Diluted Average) for the months ended in Mar. 2024 was 75.108 Mil.

IDEAYA Biosciences's Onwer Earnings Per Share for Mar. 2024 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -130.378 +4.13+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-2.6853263253125+-11.264)/75.108
=-1.87

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=41.15/-1.87
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


IDEAYA Biosciences Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of IDEAYA Biosciences's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


IDEAYA Biosciences (IDEAYA Biosciences) Business Description

Traded in Other Exchanges
Address
7000 Shoreline Court, Suite 350, South San Francisco, CA, USA, 94080
IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
Executives
Yujiro S Hata director, officer: President and CEO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Briseno Andres Ruiz officer: See Remarks C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Jason Throne officer: VP, General Counsel C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Paul A. Stone officer: SVP, General Counsel C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Darrin Beaupre officer: SVP, Chief Medical Officer C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Michael Anthony White officer: SVP, Chief Scientific Officer C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Michael P. Dillon officer: SVP, Chief Scientific Officer C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Susan L. Kelley director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Mark Lackner officer: SVP, Head of Biology C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Andrew J. Schwab 10 percent owner, Former 10% holder C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman 10 percent owner, Former 10% holder C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Scott M Rocklage 10 percent owner, Former 10% holder C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Iv, L.p. 10 percent owner, Former 10% holder 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107

IDEAYA Biosciences (IDEAYA Biosciences) Headlines

From GuruFocus

IDEAYA Announces Pricing of Public Offering

By PRNewswire 10-25-2023